

the **ADBL** report

Issue #125, March 2022

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross

The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

EXPERT COMMITTEE MEMBERS:

Fiona Clement, PhD, (Acting Chair)
Caitlin A. Clarke, BScPhm, PharmD
Margaret Gray, BSP, FCSHP
Michael Kolber, BSc, MD, CCFP, MSc
Naeem Ladhani, BScPharm
Tony Nickonchuk, BScPharm
Donna Woloschuk, BSP, PharmD, M.Ed. FCSHP

ALBERTA HEALTH LIAISON:

Andrea Nagle, BScPharm, LLB

ADMINISTRATIVE AND SCIENTIFIC SUPPORT:

Julia Chan, BSc (Pharm)
Amanda Chung, BSc (Pharm)
Sherry Dieleman, BSc (Pharm), MSc
Connie Lussier, BSP, MA

In this issue:

- **Brief Summary of Drug Review Activities**
- **Highlights of:**
 - ❖ **Products Originally Reviewed via the CDR**
 - ❖ **Drug Products Added**
 - ❖ **Changes to Currently Listed Products**

Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on January 18, 2022. The Committee reviewed Manufacturer submissions for fifteen (15) Drug Products for potential listing, or change in listing, on the ADBL. The Committee also considered information for a number of supplementary assessments of the coverage status of forty-eight (48) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, fifty-five (55) Drug Products underwent Expedited Review for listing on the ADBL effective March 1, 2022.

The following are highlights of recent changes to the ADBL and other topics of general interest. A complete list of changes, as well as the full ADBL may be accessed at <https://www.ab.bluecross.ca/dbl/publications.php>

Highlights of Products Originally Reviewed via the Common Drug Review (CDR)

The following Drug Products were reviewed by CDR and the Expert Committee and added to the ADBL effective March 1, 2022:

- **ENTYVIO* 108 mg/0.68 mL injection pen & syringe** (vedolizumab) (TAK) via Special Authorization (SA) for the indications of Crohn's Disease and Ulcerative Colitis
- **EVRYSDI* 0.75 mg/mL oral solution** (risdiplam) (HLR) via SA
- **FORXIGA* 5 mg & 10 mg tablets** (dapagliflozin propanediol monohydrate) (AZC) via Step Therapy/SA for the indication of Heart Failure

A complete list of changes, as well as the full ADBL may be accessed at <https://www.ab.bluecross.ca/dbl/publications.php>.

Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).

ABC 81171 (03/2022)

Highlights of Drug Products Added

The following Natural Health Product was reviewed by the Expert Committee and added to the *ADBL* effective March 1, 2022:

- **MK 8 8 MEQ tablet** (potassium chloride (K+)) (MTR)

The following Drug Products were reviewed by the Expert Committee and added to the *ADBL* effective March 1, 2022:

- **PANCREASE MT 2 capsule (enteric-coated pellet)** (lipase/ amylase/ protease) (VPL)
- **VYNDAMAX* 61 mg capsule** (tafamidis) (PFI) via SA

Highlights of Changes to Currently Listed Products

The interchangeable status for the following Drug Product on the *Palliative Coverage Drug Benefit Supplement (PCDBS)* has been changed effective March 1, 2022:

- **JAMP-SENNA 8.6 mg tablet** (sennosides) (JPC)

The Special Authorization criteria for coverage for the following Drug Products have been revised effective March 1, 2022:

- **SPINRAZA* 2.4 mg/mL injection** (nusinersen sodium) (BIO)
- **VYNDALIN* 20 mg capsule** (tafamidis meglumine) (PFI)

A complete list of changes, as well as the full *ADBL* may be accessed at <https://www.ab.bluecross.ca/dbl/publications.html>.

*Please refer to the current *ADBL* for explanations of coverage, including a listing of coverage criteria (where applicable).*

ABC 81171 (03/2022)